Italy looks at medicine price cuts while Spain moves on discounts
This article was originally published in Scrip
Executive Summary
The Italian government is likely to introduce medicine price cuts in a bid to save €2 billion on drug spending. Meanwhile, the Spanish cabinet recently approved a bill that will see discounts applied to state-financed patented medicines, and France is to bring forward a range of pricecuts that among other things could affect Merck & Co's antihypertensive Cozaar (losartan).
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.